Produktbeschreibung
Navitoclax (ABT-263 ) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a Ki value of Apoptosis and downregulates the expression of Survivin and TGFbeta2. Navitoclax alleviates fibrosis and induces thrombocytopenia. Navitoclax exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases[1][2][3][4][5][6].
* MwSt. und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
